Jim has over 30 years’ experience in the manufacture, quality control, development and international regulatory requirements for biopharmaceutical products. He has provided regulatory and product development advice and assistance to large and small companies. Prior to establishing Global Bioscience Solutions, Jim was employed at CSL Limited as Head of Regulatory Affairs.
Prof. John Hayball
Immunologist at University of South Australia, South Australia, Australia
Prof. John Hayball heads the Experimental Therapeutics Lab at the university of South Australia were Sementis (with Prof. John Hayball)’s oversight) conducts all preclinical immunological research and testing the efficacy of its new vaccines. John is a molecular and cellular immunologist with fundamental interests understanding the processes that control immunological tolerance and immunity in different animals, from the teleost fishes through to humans. John is interested in performing basic, translational and clinical research that aims to improve chronic and acute health outcomes, by exploring novel immunotherapeutic approaches to treat and prevent cancer, allergy and other diseases including chronic and acute infections, uncontrolled inflammation in sepsis, autoimmunity and biomaterial implant responses. In recent years John has focused on national and international cross-disciplinary collaboration leading to productive translational outcomes in human and animal health, by strategically engaging with research academics, clinicians, vets and industry partners to form integrated research programs with the capacity to address challenging health questions. He has a strong track record of project grant funding awarded from a variety of sources including NHMRC and ARC and other national, state and institutional schemes. He has also a long history of highly successful industry engagement, including biotechnology consultancies, commercial research funding and funding from industry-leveraged federal government schemes including ARC Linkage, CSIRO STEM+ and Researches-in-Business (Enterprise Connect) schemes. He has authored over 110 peer-reviewed publications.
Prof. Andreas Suhrbier
Immunologist at QIMR Berghofer Medical Research Institute, Queensland, Australia
Prof Suhrbier is a world leader in infectious diseases particularly Chikungunya and Zika virus. He is member of Global Virus Networks and Chikungunya Working Party. He has developed an internationally accepted mouse model for studying Chikungunya infection. Using his model, he has tested our Chikungunya and Zika virus vaccine and has shown that Sementis vaccine can protect mice from a virulent Chikungunya and a virulent Zika virus challenge.